Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Phase II/III, Randomized, Double-blind, Placebo Controlled, Parallel Design Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Dapagliflozin and Dapagliflozin in Combination With Saxagliptin in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria Treated With ACEi or ARB

NCT02547935 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02547935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02547935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Phase II/III, Randomized, Double-blind, Placebo Controlled, Parallel Design Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Dapagliflozin and Dapagliflozin in Combination With Saxagliptin in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria Treated With ACEi or ARB
Lead sponsor
AstraZeneca
Phase
Phase 2/3
Overall status
Completed
Start date
September 21, 2015
Completion date
May 18, 2018
Enrollment
459 (actual)
Sites
112

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus, ckd and albuminuria